Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Private biotechs received almost $4bn in venture financing in the third quarter, as the healthy financing climate showed few signs of deteriorating.